Korro Bio Inc KRRO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
-
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Korro to Participate in Upcoming Investor Conferences
-
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
-
This biotech is halting its work with Novo Nordisk and laying off more people
Trading Information
- Previous Close Price
- $9.31
- Day Range
- $8.45–9.38
- 52-Week Range
- $5.20–50.45
- Bid/Ask
- $8.00 / $8.29
- Shares Outstanding
- 14.73M
- Market Cap
- $125.02M
- Volume/Avg
- 129,734 / 152,906
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 44.44
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 57
- Website
- https://www.korrobio.com
Valuation
|
Metric
|
KRRO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.26 |
Price/Sales | 44.44 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KRRO
|
|---|---|
Quick Ratio | 9.11 |
Current Ratio | 9.55 |
Interest Coverage | — |
Quick Ratio
KRRO
Profitability
|
Metric
|
KRRO
|
|---|---|
Return on Assets (Normalized) | −44.87% |
Return on Equity (Normalized) | −73.73% |
Return on Invested Capital (Normalized) | −50.98% |
Return on Assets
KRRO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|zn@#R&r | LOCK|!R!TH | $127B | |||
| Moderna Inc
MRNA
| LOCK|L$^y>sS | LOCK|Bm | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|m^&@@H | LOCK|X@@@ | $81B | |||
| argenx SE ADR
ARGX
| LOCK|wg^dZXS | LOCK|T<c | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|jLSSY? | LOCK|#$V | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|gfq^cDR | LOCK|dGN^r | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|R^>G?Wl | LOCK|TZ!&$ | $27B | |||
| Incyte Corp
INCY
| LOCK|@J@M>Fb | LOCK|>c | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Xt$^@HK | LOCK|kh | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|zV#Bb@ | LOCK|X!^ | $14B |
United States